Previous close | 50.03 |
Open | 50.31 |
Bid | 49.80 x 1200 |
Ask | 51.32 x 1800 |
Day's range | 50.17 - 51.01 |
52-week range | 46.93 - 58.10 |
Volume | |
Avg. volume | 2,525,869 |
Market cap | 127.388B |
Beta (5Y monthly) | 0.36 |
PE ratio (TTM) | 18.28 |
EPS (TTM) | 2.79 |
Earnings date | N/A |
Forward dividend & yield | 1.75 (3.49%) |
Ex-dividend date | 26 May 2022 |
1y target est | 70.75 |
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.